THE TRIPS WAIVER AND GLOBAL HEALTH EQUITY
DOI:
https://doi.org/10.29121/granthaalayah.v13.i4.2025.6158Keywords:
Trips Agreement, Patent Waiver, Intellectual Property Rights, Covid-19 Vaccines, Global Health Equity, Public HealthAbstract [English]
This research paper critically examines the proposal for a patent waiver under the TRIPS Agreement in response to the COVID-19 pandemic, with a primary goal of evaluating its effectiveness in promoting global health equity. The study adopts a qualitative research design, employing a doctrinal legal methodology to analyze international legal frameworks, WTO documents, and scholarly literature. It assesses both the arguments supporting and opposing the PW, focusing on its potential to enhance vaccine accessibility and affordability, particularly in least developed nations. The analysis reveals that while the waiver could facilitate wider vaccine production by eliminating intellectual property barriers, it faces significant opposition due to concerns about undermining incentives for innovation and weakening the global intellectual property regime. The paper also highlights practical challenges in implementing such a waiver, including legal complexities and the absence of a robust enforcement mechanism. Furthermore, it explores existing TRIPS flexibilities, such as compulsory licensing, as alternative strategies that might balance intellectual property protection with public health needs. The findings suggest that although the patent waiver has symbolic and practical merit in addressing immediate health crises, its long-term viability as a model for future pandemics is limited. The study concludes that rather than relying solely on patent waivers, a more sustainable approach would involve strengthening domestic intellectual property legislation, promoting voluntary licensing, and fostering international cooperation to ensure equitable access to essential medicines and vaccines during global health emergencies.
Downloads
References
World Trade Organization. (1994, April 15). Agreement on Trade-Related Aspects of Intellectual Property Rights. https://www.wto.org/english/docs_e/legal_e/27-TRIPS.pdf
World Trade Organization. (2021, May 18). Waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 – Joint statement of co-sponsors (Document No. IP/C/W/677). https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W677.pdf
World Trade Organization. (2020, October 1). Extension of the transition period under TRIPS Article 66.1 for least developed country members (Document No. IP/C/W/668). https://web.wtocenter.org.tw/file/PageFile/345475/IPCW668.pdf
World Trade Organization. (2020, October 2). Waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 (Document No. IP/C/W/669). https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf
World Trade Organization. (2022, June 17). Ministerial decision on the TRIPS Agreement (Document Nos. WT/MIN(22)/30 & WT/L/1141). https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/WT/MIN22/30.pdf
Katarzyna Kolodziejczyk, K., & Kołodziejczyk, K. (2022). The EU Towards the Global South During the COVID-19 Pandemic (New edition 1, Vol. 49). Peter Lang International Academic Publishers. https://doi.org/10.3726/b20199 DOI: https://doi.org/10.3726/b20199
Rae, M. (2021). The COVID-19 vaccine void : when should patents be waived? SAGE Publications. DOI: https://doi.org/10.4135/9781529789706
Taubman, A., Wager, H., & Watal, J. (2012). A handbook on the WTO TRIPS agreement : hbk. Cambridge University Press. DOI: https://doi.org/10.30875/f6287588-en
World Trade Organization: TRIPS Waiver for COVID-19 Vaccines (R47231). (2022).
Wirten, E. H. (2004). No trespassing: authorship, intellectual property rights, and the boundaries of globalization. In No trespassing (1st ed.). University of Toronto Press. https://doi.org/10.3138/9781442620896 DOI: https://doi.org/10.3138/9781442620896
Bown, C. P. (2022). How COVID‐19 Medical Supply Shortages Led to Extraordinary Trade and Industrial Policy. Asian Economic Policy Review, 17(1), 114–135. https://doi.org/10.1111/aepr.12359 DOI: https://doi.org/10.1111/aepr.12359
Thiendej, P., & Giordano, J. T. (2022). THE ETHICS OF INTELLECTUAL PROPERTY LAW IN THE AREA OF PHARMACEUTICAL DRUGS AND VACCINES DURING TIMES OF PANDEMICS. Prajñā Vihāra, 23(1), 122-.
Kumar, M., & Bharti, N. (2023). Why patent waiver for Covid‐19 vaccines and pharmaceuticals? The Journal of World Intellectual Property, 26(2), 195–226. https://doi.org/10.1111/jwip.12269 DOI: https://doi.org/10.1111/jwip.12269
Mercurio, B. C. (2021). WTO Waiver from Intellectual Property Protection for COVID-19 Vaccines and Treatments: A Critical Review. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3789820 DOI: https://doi.org/10.2139/ssrn.3789820
Agejoh, P. A. (2022). Temporary Waiver of Patent Rights in Public Health Emergencies: Inadequacy of Provisions during the COVID-19 Crisis. The African Review, 50(3), 300–329. https://doi.org/10.1163/1821889x-bja10032 DOI: https://doi.org/10.1163/1821889x-bja10032
KOHLER, J., WONG, A., & TAILOR, L. (2022). Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders. Health and Human Rights, 24(2), 159–176.
Paquin, S., & Plouffe-Malette, K. (2023). The WTO and the Covid‐19 “Vaccine Apartheid”: Big Pharma and the Minefield of Patents. Politics and Governance, 11(1), 261–271. https://doi.org/10.17645/pag.v11i1.6177 DOI: https://doi.org/10.17645/pag.v11i1.6177
Erfani, P., Binagwaho, A., Jalloh, M. J., Yunus, M., Farmer, P., & Kerry, V. (2021). Intellectual property waiver for covid-19 vaccines will advance global health equity. BMJ (Online), 374, n1837–n1837. https://doi.org/10.1136/bmj.n1837 DOI: https://doi.org/10.1136/bmj.n1837
Aerts, R. J. (2022). COVID-19 vaccines, patents and an IP waiver. Journal of Intellectual Property Law & Practice, 17(11), 940–945. https://doi.org/10.1093/jiplp/jpac097 DOI: https://doi.org/10.1093/jiplp/jpac097
Dasari, N. (2023). Giving the World a Shot: Increasing Access to COVID-19 Vaccines by Expanding Local Production. New York University Journal of International Law & Politics, 55(3), 783-.
Sekalala, S., Forman, L., Hodgson, T., Mulumba, M., Namyalo-Ganafa, H., & Meier, B. M. (2021). Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine. BMJ Global Health, 6(7), e006169-. https://doi.org/10.1136/bmjgh-2021-006169 DOI: https://doi.org/10.1136/bmjgh-2021-006169
Thambisetty, S., McMahon, A., McDonagh, L., Kang, H. Y., & Dutfield, G. (2022). ADDRESSING VACCINE INEQUITY DURING THE COVID-19 PANDEMIC: THE TRIPS INTELLECTUAL PROPERTY WAIVER PROPOSAL AND BEYOND. Cambridge Law Journal, 81(2), 384–416. https://doi.org/10.1017/S0008197322000241 DOI: https://doi.org/10.1017/S0008197322000241
Ison, M. G., Wolfe, C., & Boucher, H. W. (2020). Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. JAMA, 323(23), 2365–2366. https://doi.org/10.1001/jama.2020.8863 DOI: https://doi.org/10.1001/jama.2020.8863
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., … Lane, H. C. (2020). Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/nejmoa2007764 DOI: https://doi.org/10.1056/NEJMoa2007764
Mermelstein, S., & Stevens, H. (2021). TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines. Pharmaceutics, 14(1), 48-. https://doi.org/10.3390/pharmaceutics14010048 DOI: https://doi.org/10.3390/pharmaceutics14010048
Addor, F. (2023). How (Not) to Sleepwalk into the Next Pandemic. International Review of Intellectual Property and Competition Law. DOI: https://doi.org/10.1007/s40319-023-01332-9
Mitchell, A. D., Taubman, A., & Samlidis, T. (n.d.). The Legal Character and Practical Implementation of a TRIPS Waiver for COVID-19 Vaccines. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.4248110 DOI: https://doi.org/10.2139/ssrn.4248110
Zaman, K. (2022). The Waiver of Certain Intellectual Property Rights Provisions of the TRIPS for the Prevention, Containment and Treatment of COVID-19: A Review of the Proposal under WTO Jurisprudence. European Journal of Risk Regulation, 13(2), 295–310. https://doi.org/10.1017/err.2021.60 DOI: https://doi.org/10.1017/err.2021.60
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nguyen Tung Lam
This work is licensed under a Creative Commons Attribution 4.0 International License.
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
